Read More Pharma Industry News Viatris (Nasdaq: VTRS) exits Biocon Biologics with $815m deal as biosimilars reentry accelerates Viatris unlocks $815M from Biocon Biologics exit and regains biosimilars access. Find out how this reshapes its 2026 global pharma strategy. byVenkateshDecember 7, 2025